Obesity and Resistance to Cancer Chemotherapy: Interacting Roles of Inflammation and Metabolic Dysregulation

Clinical Pharmacology & TherapeuticsVolume 96, Issue 4 p. 458-463 State of the Art Obesity and Resistance to Cancer Chemotherapy: Interacting Roles of Inflammation and Metabolic Dysregulation L M Lashinger, L M Lashinger Department of Nutritional Sciences, University of Texas at Austin, Austin, Texas, USASearch for more papers by this authorE L Rossi, E L Rossi Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina, USASearch for more papers by this authorS D Hursting, Corresponding Author S D Hursting [email protected] Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina, USASearch for more papers by this author L M Lashinger, L M Lashinger Department of Nutritional Sciences, University of Texas at Austin, Austin, Texas, USASearch for more papers by this authorE L Rossi, E L Rossi Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina, USASearch for more papers by this authorS D Hursting, Corresponding Author S D Hursting [email protected] Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina, USASearch for more papers by this author First published: 24 June 2014 https://doi.org/10.1038/clpt.2014.136Citations: 7Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract The prevalence of obesity, an established risk factor for many chronic diseases, including several types of cancer, has risen steadily over the past four decades in the United States and worldwide. To date, research in this area has focused on the epidemiologic associations between obesity and cancer risk, as well as on the mechanisms underlying those associations. However, an emerging but understudied issue of clinical importance is the diminution of chemotherapeutic efficacy in obese cancer patients. The mechanisms underlying the negative impact of obesity on therapeutic responses are likely multifactorial. The effects of obesity on chemotherapy drug pharmacokinetics and dosage have been extensively reviewed elsewhere, so this review will focus on the interplay among obesity, increased inflammation, metabolic perturbations, and chemoresistance. The ultimate goal of this review is to delineate areas for future research that could lead to the identification of new targets and strategies for improved cancer outcomes in obese patients. Clinical Pharmacology & Therapeutics (2014); 96 4, 458–463. doi:10.1038/clpt.2014.136 Citing Literature Volume96, Issue4InflammationOctober 2014Pages 458-463 RelatedInformation